Table 4.
Second primary malignancies
| FL (n = 124) |
MZL (n = 28) |
All patients (N = 152) |
|
|---|---|---|---|
| Any second primary malignancy, n (%) | 13 (10) | 5 (18) | 18 (12) |
| Nonmelanoma skin cancer | 3 (2) | 0 | 3 (2) |
| Melanoma | 1 (1) | 0 | 1 (1) |
| t-MDS/t-AML | 5 (4) | 3 (11) | 8 (5) |
| Colorectal cancer | 1 (1) | 0 | 1 (1) |
| B-ALL/AML | 1 (1) | 0 | 1 (1) |
| Anal/rectal cancer | 1 (1) | 0 | 1 (1) |
| Prostate cancer | 1 (1) | 0 | 1 (1) |
| Neuroendocrine tumor | 0 | 1 (4) | 1 (1) |
| Breast cancer | 0 | 1 (4) | 1 (1) |
ALL, acute myeloid leukemia; AML, acute myeloid leukemia; B-ALL, B-cell acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; t, therapy-related. t-MDS/t-AML are events of MDS or AML that have been identified as being likely related to prior chemotherapy before the first axi-cel infusion.